Did you know Groupe Servier started in 1954? It wasn’t always a global pharmaceutical giant. It began humbly in Orleans France with just nine employees. Jacques Servier a visionary leader built it from the ground up. His dedication to research is a cornerstone of the company’s identity. Today Groupe Servier stands as a testament to his ambition.
Groupe Servier is a major player in the pharmaceutical world. It’s the leading independent French pharmaceutical company. It’s also the second-largest in the country. The company boasts a global reach with branches in 149 countries. It achieves a remarkable 82% of its sales internationally. This global presence is a far cry from its modest beginnings.
The company’s commitment to research and development is impressive. It allocates nearly 25% of its turnover to this crucial area. A dedicated team of 3000 employees focuses solely on R&D. This dedication helps fuel innovation. It results in a wide range of products. Groupe Servier manufactures and markets medicines for various conditions.
Groupe Servier’s impact extends beyond its impressive sales figures. It has production sites that produced 853 million drug boxes in 2013. Its Clinical Support Unit in Gidy near Orleans is the largest of its kind in Europe. This unit plays a critical role in drug development. It supplies drugs for clinical trials across the continent. Groupe Servier is a significant contributor to global health.
However Groupe Servier’s history isn’t without controversy. The Mediator drug originally developed for weight loss in diabetics was later prescribed off-label for dieting. It was linked to hundreds perhaps thousands of deaths in France. In 2021 a French court found Servier guilty of deception and manslaughter. The company paid substantial fines. It was forced to pay millions in damages to victims.
Despite this dark chapter Groupe Servier continues its operations. It’s constantly innovating. It’s expanding its research collaborations. It is active in cardiology diabetes metabolic diseases neurology oncology and orphan diseases. The company has partnered with numerous organizations. It continues to develop new treatments for a wide range of health conditions. Groupe Servier’s journey is one of remarkable growth. It’s also a story of both triumph and tribulation. It stands as a reminder of the complexities of the pharmaceutical industry.